Avid Bioservices Shares Jump as RBC Boosts Price Target After Bookings Beat
Avid Bioservices (CDMO) shares jumped 19% in recent Tuesday trading as RBC Capital Markets raised its price target to $12 from $8 after the company's bookings topped the analyst's estimate.
Bookings in fiscal Q1 at $66 million beat RBC's forecast of $36 million, the company's results showed Monday. "Improving bookings momentum" spurred the higher price target, RBS said, affirming its outperform rating on the stock.
The company reiterated revenue guidance for fiscal 2025 of $160 million to $168 million, supported by growing bookings and backlog standing at $219 million, RBC said.
Price: 10.62, Change: +1.67, Percent Change: +18.66
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。